Prosecution Insights
Last updated: November 04, 2026
Application No. 17/740,094

Tagged Compounds for Detection and Assay of Small Molecules

Non-Final OA §112§DP
Filed
May 09, 2022
Examiner
NGUYEN, NAM P
Art Unit
1678
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aveta Life Inc.
OA Round
5 (Non-Final)
55%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
187 granted / 341 resolved
-5.2% vs TC avg
Strong +49% interview lift
Without
With
+48.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
50 currently pending
Career history
397
Total Applications
across all art units

Statute-Specific Performance

§101
4.9%
-35.1% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
15.6%
-24.4% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 341 resolved cases

Office Action

§112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 05/11/2026 has been entered. Status of Claims Claims 1-2, 5, 7-8, 10-11, 18 and 20 are pending and under examination. Withdrawn Rejections In light of the amendments, the 35 U.S.C. 112(a) written description rejection over claims 1-2, 5, 7-8 and 10-11 is hereby withdrawn. Claim Objections Claims 1, 7-8, 10 and 18 are objected to because of the following informalities: The claims recite “a competitive ligand bound to linker” should be – a competitive ligand bound to polyethylene glycol linker – to be consistent to the above recitations to indicate where the binding occurs. The claims also recite “its complement” should be – the full complement thereof – to represent the complement of the claimed sequences. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 18 and 20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claim 18 recites the limitation of “wherein the linker is a double stranded DNA sequence of 5’…..-3’ (SEQ ID NO: 1) and its complement” (emphasis added). Applicant’s response dated 05/11/2026 stated that support for these amendments can be found throughout the specification as originally filed. However, examiner was unable to find support for the Linker is merely the claimed DNA SEQ ID NO: 1 or its complement for attaching to the ligand and fluorescein. In particular, the claimed sequence alone would not have the ability to bind to the ligand nor the fluorescein without other chemical structures. Meanwhile, the specification has not disclosed the Linker consists of SEQ ID NO: 1 (as claimed) for attachments. Therefore, the limitations would introduce new matter because the specification fails to provide a direction or blaze marks to said limitations. Claim 20 is rejected as being dependent from claim 18. Claims 18 and 20 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The MPEP states that the purpose of the written description requirement is to ensure that the inventor had possession, as of the filing date of the application, of the specific subject matter later claimed. The MPEP lists factors that can be used to determine if sufficient evidence of possession has been furnished in the disclosure of the application. These include “level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention.” MPEP 2163. MPEP § 2163 further states that, for a claimed genus, the written description requirement may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. The nature of claims relates to a biological probe configured to competitively assay small molecules comprising a ligand that is attached to a linker that is attached to a signaling molecule, wherein the linker is a double stranded DNA sequence of 5' CCT CCA TTA CGC GCG ACC -3' (SEQ ID NO. 1) and its complement; wherein the signaling molecule is fluoresceine. The claims are broad and generic to having the biological probe comprising dsDNA as the linker. Note that the recitation of “a double stranded DNA sequence of… (SEQ ID NO: 1)” includes any portion of SEQ ID NO: 1. Implicit in the claims is that such fluorescein and ligand attached to the dsDNA as a whole must possess certain functional characteristics; namely to produce the claimed function for measurements by the fluorescein and ligand. Mitchell et al. (WO2008/100161A1, published 2008) teach a spacer of PEG is conjugated to a cortisol (i.e., ligand) to be immobilized as a sensor on the senor surface (892 dated 06/20/2023). Peeters et al. (“Impact of spacers on the hybridization efficiency of mixed self-assembled DNA/alkanethiol films”, Biosensors and Bioelectronics, vol. 24, pgs. 72-77, published 2008) teach immobilization of DNA strands is an essential step in the development of any DNA biosensor and evaluating spacers to assess their impact on sensitivity and reproducibility (see abstract). Peeters further teaches that there is a considerable and clear impact of spacers on the biosensor performance (see abstract and conclusion). Peeters teaches dynamic range was negatively affected and the maximum hybridization signal dropped from spacers (see pg. 76, last para. right col., section 3.3). Meanwhile, the instant specification has only provided specific examples of linking fluorescein and ligand through DNA with PEG at specific positions. The disclosed fluoresceins are attached to the DNA nucleotide sequences at the phosphate group (see Figs. 4-5, as filed). Additionally, the instant specification has only provided a single example having a PEG spacer conjugated to the claimed competitive ligand and DNA (see Fig. 4, as filed) as a biological probe configured to completely assay small molecules. The specification lacks guidance to only use DNA as the sole linker for coupling to the ligand. In particular, the specification has disclosed a specific PEG spacer is required in the presence of the DNA Linker (see Fig. 4, as filed) while attached to the DNA sequence at a phosphate group of a particular nucleotide base to produce the claimed functions. Thus, the specification lacks guidance to a wide range of dsDNA with two dinucleotide (i.e., any portion of SEQ ID NO: 1) that coupled to the claimed fluorescein and ligand to provide the claimed probe configured for competitive assay. The courts have stated that “tossing out the mere germ of an idea does not constitute enabling disclosure.” Genentech, 108 F.3d at 1366 (quoting Brenner v. Manson, 383 U.S. 519, 536 (1966) (stating, in context of the utility requirement, that “a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion”)). “[R]easonable detail must be provided in order to enable members of the public to understand and carry out the invention.” Id. In this instant case, such reasonable detail is lacking in these claims. For example, chemical sensitivities would encompass a wide range of chemical structures which has not been described in the instant specification. There is nothing in the application, as filed, to suggest that, for example, the dsDNA sequences below 14 nucleotides (as claimed) would be able to produce a similar competitive outcome. Meanwhile, Peeters teaches that there is a considerable and clear impact of spacers on the biosensor performance (see abstract and conclusion). Peeters teaches dynamic range was negatively affected and the maximum hybridization signal dropped from spacers (see pg. 76, last para. right col., section 3.3). Mitchell requires a PEG spacer for cortisol ligand to be immobilized as a sensor on the senor surface. Therefore, based on the prior art and the instant disclosure, there would be undue experimentations to determine which DNA length and position attachments of the claimed probe would produce the claimed outcome. As stated above, the state of the art teaches the unpredictability associated with fluorophore signaling when attached to DNA sequences. Due to the state of the prior art and the lack of the instant specification in not disclosing a representative number of species for the dsDNA with two nucleotides and dsDNA as only the linker. In summary, due to the state of the prior art and the lack of the instant specification in not disclosing a representative number of species, as well as the lack of direction/guidance or working examples, the specification fails to teach the skilled artisan how to make the claimed invention without undue experimentations. Therefore, the claims fail to comply with the written description requirement of a representative number species. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 18 and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 18 recites a double stranded DNA sequence but the sequence provided in the claim is a single stranded DNA. Thus, the claim is unclear to the structure of the double stranded DNA sequence with only a single stranded DNA as claimed. Additionally, the claim is being rejected as being incomplete for omitting essential elements, such omission amounting to a gap between the elements. See MPEP § 2172.01. The omitted elements are the linker’s elements for attaching DNA sequence to the ligand and fluorescein. Based on the amendments of “linker is a double stranded DNA sequence”, the claim is unclear to the metes and bounds of the structures of the biological probe. The structure of the ligand is generic. Therefore, it is unclear to what are the structures that are providing the attachments between these elements to produce the claimed probe. Claim 20 is being rejected as being dependent from claim 18. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 8 and 10-11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 18830858 (‘858) in view of Hudson et al. (US2012/0329035A1, published 12/27/2012). Application ‘858 recites a biological probe configured to competitively assay a small molecule, the biological probe comprising a competitive ligand that is attached to a linker that is attached to a signaling molecule, wherein the linker includes a double stranded DNA sequence of 5'-GGTATTATGCGCGAAGGAA-3' and its complement. Thus, the claimed DNA sequences of Application ‘858 recites the instant claimed sequence of SEQ ID NOs: 2 and 3. Claim 2 recites wherein the signaling molecule is a fluorophore or a dye. Application ‘858 does not recite polyethylene glycol and fluorescein. Hudson teaches Cholesterol-PEG-fluorescein (see para. [0075]). However, it would have been obvious to the person of ordinary skill in the art at the time of filing to have used the biological probe as recited in Application ‘858 with PEG and fluorescein as taught by Hudson because the Application recites any fluorophore or dye can be attached to the claimed DNA sequence and Hudson teaches PEG-fluorescein can bind to a competitive ligand such as cholesterol. Response to Arguments Applicant's arguments filed 05/11/2026 have been fully considered but they are not persuasive for claims 18 and 20 under the written description rejection. Applicant argues on pages 6-7 that the amendments have overcome the written description of all the claims. The arguments are not found persuasive for claims 18 and 20 as the claims do not have the necessary structures to produce the claimed function (see above). In particular, the disclosure does not provide a dsDNA sequence that is 2 nucleic acid long as the sole linker to attach fluorescein and ligand nor does the specification provide evidence of a linking ligand to DNA linker without PEG at specific position of the DNA sequence (see Figs. 4-5, as filed). Note that the recitation of “a double stranded DNA sequence of…” includes dinucleotide dsDNA. Meanwhile, the claims also invoked a new matter rejection as the specification has not provided support for the amendments of claims 18 and 20. Thus, the rejection is maintained for these claims. Allowable Subject Matter Claims 1-2, 5 and 7 would be allowable if rewritten or amended to overcome the objection, as set forth in this Office action above. The closest prior art reference of record is Fahmy but the reference fails to teach or reasonably suggest a probe with the claimed sequences. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NAM P NGUYEN whose telephone number is (571)270-0287. The examiner can normally be reached Monday-Friday (8-4). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory Emch can be reached at (571)272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /N.P.N/Examiner, Art Unit 1678 /SHAFIQUL HAQ/Primary Examiner, Art Unit 1678
Read full office action

Prosecution Timeline

Show 6 earlier events
Jun 20, 2024
Request for Continued Examination
Jul 23, 2024
Response after Non-Final Action
Feb 07, 2025
Non-Final Rejection mailed — §112, §DP
Aug 07, 2025
Response Filed
Nov 10, 2025
Final Rejection mailed — §112, §DP
May 11, 2026
Request for Continued Examination
May 12, 2026
Response after Non-Final Action
Sep 23, 2026
Non-Final Rejection mailed — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782345
ADDITIVE, SURFACE TREATMENT AGENT, SURFACE-MODIFIED LATEX PARTICLES, METHOD FOR PRODUCING SURFACE-MODIFIED LATEX PARTICLES, REAGENT FOR LATEX AGGLUTINATION REACTION, KIT, AND METHOD FOR DETECTING TARGET SUBSTANCE
4y 3m to grant Granted Nov 03, 2026
Patent 12753235
FC-BINDING PROTEIN HAVING IMPROVED ACID STABILITY, PRODUCTION METHOD FOR SAID PROTEIN, AND ANTIBODY-ADSORBING AGENT USING SAID PROTEIN
6y 1m to grant Granted Oct 06, 2026
Patent 12742774
METHODS FOR DETECTING ABERRANT RESULTS CAUSED BY INCOMPLETE DELIVERY OF A POLYHAPTEN REAGENT IN IMMUNOASSAYS
4y 11m to grant Granted Sep 22, 2026
Patent 12730109
TARGETED SIALIC ACID LABELING COMPOUNDS, METHODS, AND USES THEREOF
5y 4m to grant Granted Sep 08, 2026
Patent 12724033
CHEMILUMINESCENT COMPOUNDS FOR MULTIPLEXING
4y 7m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+48.7%)
3y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 341 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month